The value of programmed death ligand 1 expression in cancer patients treated with neoadjuvant chemotherapy

Malika Al-Dughaishi, Asem Shalaby*, Khawla Al-Ribkhi, Ammar Boudaka, Mohamed Boulassel, Jumana Saleh

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.

Original languageEnglish
Pages (from-to)e277-e283
JournalSultan Qaboos University Medical Journal
Volume19
Issue number4
DOIs
Publication statusPublished - Nov 1 2019

Keywords

  • Cancer
  • Neoadjuvant Therapy
  • Programmed Cell Death 1 Ligand 1
  • Programmed Cell Death 1 Receptor

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The value of programmed death ligand 1 expression in cancer patients treated with neoadjuvant chemotherapy'. Together they form a unique fingerprint.

Cite this